May 21, 2020
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
May 07, 2020
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
Mar 03, 2020
Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update
Jan 10, 2020
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
May 06, 2019
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
Apr 01, 2019
Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting
Mar 07, 2019
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
Feb 27, 2019
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
Jan 07, 2019
Syndax Highlights 2019 Clinical and Corporate Outlook
Nov 05, 2018
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
Oct 25, 2018
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer
Sep 25, 2018
Syndax Announces Changes to its Board of Directors
Aug 07, 2018
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
May 30, 2018
Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
May 17, 2018
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
May 08, 2018
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
Apr 25, 2018
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
Mar 05, 2018
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
Jan 10, 2018
Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer